Picard Medical (PMI) EBITDA (2024 - 2026)

Picard Medical (PMI) has 3 years of EBITDA data on file, last reported at -$7.6 million in Q1 2026.

• For the quarter ending Q1 2026, EBITDA fell 36.61% year-over-year to -$7.6 million; the trailing twelve-month figure through Mar 2026 stood at -$29.1 million (down 17.99% YoY), and the FY2025 full-year result was -$27.1 million, down 28.39% from the prior year.
• EBITDA for Q1 2026 stood at -$7.6 million, down from -$4.3 million in the prior quarter.
• Across five years, EBITDA topped out at -$4.1 million in Q2 2024 and bottomed at -$10.5 million in Q3 2025.
• The 3-year median for EBITDA is -$6.5 million (2024), against an average of -$6.7 million.
• Peak annual rise in EBITDA reached 51.38% in 2025, while the deepest fall reached 68.73% in 2025.
• A 3-year view of EBITDA shows it stood at -$8.8 million in 2024, then soared by 51.38% to -$4.3 million in 2025, then slumped by 76.99% to -$7.6 million in 2026.
• The last three EBITDA figures came in at -$7.6 million (Q1 2026), -$4.3 million (Q4 2025), and -$10.5 million (Q3 2025), per Business Quant data.

Peer Comparison